InforMing the PAthway of COPD Treatment (IMPACT) trial: fibrinogen levels predict risk of moderate or severe exacerbations

BACKGROUND: Fibrinogen is the first qualified prognostic/predictive biomarker for exacerbations in patients with chronic obstructive pulmonary disease (COPD). The IMPACT trial investigated fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) triple therapy versus FF/VI and UMEC/VI in patients wi...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Respir Res
Main Authors: Singh, Dave, Criner, Gerard J., Dransfield, Mark T., Halpin, David M. G., Han, MeiLan K., Lange, Peter, Lettis, Sally, Lipson, David A., Mannino, David, Martin, Neil, Martinez, Fernando J., Miller, Bruce E., Wise, Robert, Zhu, Chang-Qing, Lomas, David
Formato: Artigo
Idioma:Inglês
Publicado em: BioMed Central 2021
Assuntos:
Research
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC8080358/
https://ncbi.nlm.nih.gov/pubmed/33910578
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12931-021-01706-y
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados